Showing results (1751-1760 of 1,814) with videos related to
Sort By:
Pageof 182
Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancerJ H Chung, D Pavlick, R Hartmaier, et al.The Lancet. Oncology|October 24, 2023
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Science (New York, N.Y.)|February 19, 2021
A global environmental crisis 42,000 years agoAlan Cooper, Chris S M Turney, Jonathan Palmer, et al.Journal for Immunotherapy of Cancer|April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinomaPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.Science (New York, N.Y.)|May 19, 2018
Ancient genomes document multiple waves of migration in Southeast Asian prehistoryMark Lipson, Olivia Cheronet, Swapan Mallick, et al.Nature Communications|April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitorsChester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.Pageof 182